A Randomized, Open-label, Active-Controlled and Blinded-Endpoint Trial Comparing the Antiplatelet Effects of Ticagrelor Plus Aspirin Versus Clopidogrel Plus Aspirin in Chinese Patients With High-risk Transient Ischemic Attack or Minor Stroke.

Trial Profile

A Randomized, Open-label, Active-Controlled and Blinded-Endpoint Trial Comparing the Antiplatelet Effects of Ticagrelor Plus Aspirin Versus Clopidogrel Plus Aspirin in Chinese Patients With High-risk Transient Ischemic Attack or Minor Stroke.

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 22 Mar 2017

At a glance

  • Drugs Ticagrelor (Primary) ; Aspirin; Clopidogrel
  • Indications Stroke
  • Focus Pharmacodynamics; Therapeutic Use
  • Acronyms PRINCE
  • Most Recent Events

    • 16 Mar 2017 Planned End Date changed from 1 Oct 2016 to 14 Mar 2018.
    • 24 Feb 2017 Results (n=580; data cut off: Nov 2016) presented at the 42nd International Stroke Conference
    • 17 May 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top